XML 20 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 3,300 $ 3,226
Accounts receivables, net of allowance for credit losses of $78 million and $95 million as of December 31, 2024 and December 31, 2023, respectively 3,059 3,408
Inventories 3,007 4,021
Prepaid expenses 1,006 1,255
Other current assets 409 504
Assets held for sale 1,771 70
Total current assets 12,552 12,485
Deferred income taxes 1,799 1,812
Other non-current assets 462 470
Property, plant and equipment, net 4,581 5,750
Operating lease right-of-use assets 367 397
Identifiable intangible assets, net 4,418 5,387
Goodwill [1] 15,147 17,177
Total assets 39,326 43,479
Current liabilities:    
Short-term debt 1,781 1,672
Sales reserves and allowances 3,678 3,535
Accounts payables 2,203 2,602
Employee-related obligations 624 611
Accrued expenses 2,792 2,771
Other current liabilities 1,020 1,044
Liabilities held for sale 698 13
Total current liabilities 12,796 12,247
Long-term liabilities:    
Deferred income taxes 483 606
Other taxes and long-term liabilities 4,028 4,019
Senior notes and loans 16,002 18,161
Operating lease liabilities 296 320
Total long-term liabilities 20,809 23,106
Commitments and contingencies, see note 12
Total liabilities 33,606 35,353
Redeemable non-controlling interests 340 0
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; December 31, 2024 and December 31, 2023: authorized 2,495 million shares; issued 1,240 million shares and 1,227 million shares, respectively 58 57
Additional paid-in capital 27,764 27,807
Accumulated deficit (15,173) (13,534)
Accumulated other comprehensive loss (3,148) (2,697)
Treasury shares as of December 31, 2024 and December 31, 2023: 107 million and 106 million ordinary shares, respectively (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 5,373 7,506
Non-controlling interests 7 620
Total equity 5,380 8,126
Total liabilities, redeemable non-controlling interests and equity $ 39,326 $ 43,479
[1] Cumulative goodwill impairment as of December 31, 2024, December 31, 2023 and December 31, 2022 was approximately $29.55 billion, $28.3 billion and $27.6 billion, respectively.